Managing High-Risk NMIBC
Transcript: Neal Shore on UGN-102 for NMIBC
Dr. Neal Shore
Interview recorded February 2025. All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
Some very nice data was presented looking at the combination, by Sandip Prasad, of the UGN-102 from the ATLAS and the ENVISION trial. It's the reverse thermal hydrogel technology of mitomycin C, the UGN-102. I was involved in the ATLAS study and Sandip did a very nice job of kind of combining some of the results of both ATLAS and ENVISION. That particular drug formulation is pending FDA review. So I think that that was a very nice and an interesting study to continue to review, and also see its potential for its use as an ablative strategy. Where you have low-grade intermediate-risk patients, that was a separate presentation And for patients that you may want to avoid TURBT, and look at this formulation, the UGN-102, as an ablative formulation, I think more and more we're gonna be seeing other early-phase studies that are looking at a blade of strategies.
Meaning, can we avoid unnecessary TURBTs? I realise that, you know, as urologists, we're trained to do that, but you know, sometimes if we can avoid the anaesthetic consideration, the repetitive biopsies, even sometimes there's supply chain and person power shortages, if an intravesical therapeutic can be given in the clinic, that's as good, maybe better, than repetitive TURBT, I think that's an interesting strategy for us all to be aware of.
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.